Dasatinib-Related Chylothorax

Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manife...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yen-Min, Wang, Cheng-Hsu, Huang, Jen-Seng, Yeh, Kun-Yun, Lai, Chien-Hong, Wu, Tsung-Han, Chang, Pei-Hung, Chang, Yueh-Shih, Lan, Yii-Jenq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439910/
https://www.ncbi.nlm.nih.gov/pubmed/25805678
http://dx.doi.org/10.4274/tjh.2012.0196
Descripción
Sumario:Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manifestations, pathophysiology, management, and prognosis are not fully understood. Here we report a 40-year-old woman presenting with chylothorax following dasatinib use. We propose the hypothesis of its mechanism as well as offering a review of the relevant literature.

Ejemplares similares